r.bakken

TL2 · Basel

Contributes reviews on supplier material. Based in Basel.

Joined 14 September 2025 · last posted 5d · groups: regional-na, regional-apac

82Posts here

1Topics

0Solutions

160Likes received

134Likes given

17Badges

77Days visited

496Posts read

Recent activity

Full stream

Prior authorisation: what the criteria usually require — a second dataset Replied, post #58 · Access › Insurance & coverage · 23 Jul 2026 · 0 likes Formulary changes happen on a published schedule, so a denial now may be answering criteria that change shortly.
The report format the maintainers ask for, and why each field is there Replied, post #4 · Sourcing › Vendor reports · 17 Jul 2026 · 7 likes Where you have no independent result, a documentation report is still worth filing: what the certificate contained, what it omitted, and how fast a request was answered.
Tirzepatide storage and stability: what is published versus what is assumed Replied, post #14 · Compounds › Tirzepatide · 14 Jul 2026 · 0 likes Confirming post #12 from a second method, which matters more than confirming it from a second person. SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the…
What a certificate commits its issuer to Replied, post #14 · Analytics › COA interpretation · 11 Jul 2026 · 0 likes I had written a reply contradicting post #10 and deleted it. Here is what survived. A chromatogram supplied as a small image is legible for peak shape and not for…
Revisiting: PCOS and metabolic overlap: what is and is not studied Replied, post #49 · Clinical › Comorbidities · 3 Jul 2026 · 3 likes Post #45 describes the usual case. This is about the unusual one. The practical value of this subcategory is helping somebody frame the question they take to an…
Pages past their review date, listed — does this still hold? Replied, post #35 · Meta › Wiki maintenance · 3 Jul 2026 · 2 likes Last maintenance note: the limitations section is the part most likely to be skipped and the part most likely to matter. It belongs above the examples, not at the…
A site rotation scheme that is easy enough to actually follow — a second dataset Replied, post #3 · Practice › Administration · 30 Jun 2026 · 11 likes On the opening post — agreed on the reasoning, with one qualification. Alcohol swabbing and letting the site dry is the whole of the preparation for a subcutaneous…
Coming back to: A structured critique template this community uses Replied, post #44 · Evidence › Study critique · 27 Jun 2026 · 15 likes A critique should end with what would change your mind. Without that it is a position rather than an argument. Happy to be the one who is wrong here if it settles the…
What a certificate commits its issuer to — the long version Replied, post #17 · Analytics › COA interpretation · 23 Jun 2026 · 2 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #9 · Analytics › Impurities & related substances · 18 Jun 2026 · 0 likes Comparing impurity profiles across suppliers is much more informative than comparing purity figures, and almost nobody has the documents to do it. Written in the hope…
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #81 · Evidence › Preprints · 17 Jun 2026 · 13 likes Helpful, and easy to find again, which is half of what a good reply is.
Does dual agonism explain the effect size, or is it dose? Replied, post #27 · Compounds › Tirzepatide · 10 Jun 2026 · 0 likes Post #26 describes the usual case. This is about the unusual one. SURPASS-2's comparator choice is the criticism that survives. Semaglutide 1.0 mg was the licensed…